List view / Grid view
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, is this a valid belief at the present stage of development of the immune therapy field?
A certain macrophage phenotype is more effective than another phenotype commonly used in cell therapy for infiltrating tumours.
Don’t miss out on the easier way to do flow cytometry. Learn how to bring speed, throughput, multiplexing and miniaturization, to your bench.
Haematology research is a cradle of innovation, with many firsts in therapeutic approaches utilising the latest technology for the treatment of blood cancers. Anas Younes, Senior Vice President, Head of Haematology Oncology Research and Development at AstraZeneca, envisions a future where potential cures are within reach for more blood cancers…
Dr Rob van Montfort, a leading researcher at the Centre for Cancer Drug Discovery (CCDD) within The Institute of Cancer Research, London, is at the forefront of cancer drug discovery. Focusing on protein-ligand interactions, his work utilises structural biology and biochemical methods to help the discovery of novel small-molecule drugs…
Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.
Researchers have found that reducing glycosylation on the T cell surface may offer new approaches to cancer immunotherapy.
An epitope on CD95 receptor causes tumour cells to self-destruct and may prolong benefits of CAR T-cell therapy for solid tumours.
Listen to this podcast where we dive into genetic engineering, its role and relationship with allogeneic immunotherapy.
Extracellular vesicles loaded with mRNA encoding interferon-gamma offers promise for treating difficult tumours.
A recent scientific collaboration, led by the Institute of Nuclear Physics of the Polish Academy of Sciences, has overcome measurement challenges, enabling reliable cancer diagnosis.
New open-source computational method called Spectra improves analysis of single-cell transcriptomic data.
Researchers have successfully demonstrated the potential of using a combination of inhibitors to effectively curb tumour growth and stave off relapses in patients afflicted with specific cancers.
In this interview with Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, we discover research uncovering a central factor contributing to anti-PD-1 resistance in cancer immunotherapy.
We exclusively interview Dr Ali Roghanian, Associate Professor at the University of Southampton, UK, Ali is a leading researcher at the forefront of immunotherapy advancements. With a keen focus on the inhibitory IgG FcγRIIB receptor, join us as we dive into Ali’s findings, showcasing the complexities of FcγRIIB and its…
